Aligos Therapeutics Faces Nasdaq Delisting Notice
Ticker: ALGS · Form: 8-K · Filed: May 31, 2024 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
TL;DR
Nasdaq's coming for Aligos's listing, might get booted.
AI Summary
Aligos Therapeutics, Inc. filed an 8-K on May 29, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is facing potential delisting from the Nasdaq Stock Market due to not meeting certain continued listing standards.
Why It Matters
This filing indicates Aligos Therapeutics may be delisted from the Nasdaq, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its operations and shareholder value.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange where the company is listed and faces delisting
- May 29, 2024 (date) — Date of the earliest event reported
FAQ
What specific continued listing rule or standard has Aligos Therapeutics failed to satisfy?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which particular rule was violated in the provided text.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated May 29, 2024.
What is the company's principal executive office address?
The address is One Corporate Dr., 2nd Floor, South San Francisco, CA 94080.
What is the company's telephone number?
The company's telephone number is (800) 466-6059.
What is the SEC file number for Aligos Therapeutics, Inc.?
The SEC file number is 001-39617.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-05-31 16:05:56
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
Filing Documents
- d808483d8k.htm (8-K) — 23KB
- 0001193125-24-151729.txt ( ) — 145KB
- algs-20240529.xsd (EX-101.SCH) — 3KB
- algs-20240529_lab.xml (EX-101.LAB) — 18KB
- algs-20240529_pre.xml (EX-101.PRE) — 11KB
- d808483d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: May 31, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer